CSIMarket Company Name, Ticker, Customers, else..
 
Catalyst Pharmaceuticals Inc   (NASDAQ: CPRX)
 

Catalyst Pharmaceuticals Inc's Suppliers Performance

CPRX's Supply Chain



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

 
CPRX Costs vs Sales of Suppliers Growth Catalyst Pharmaceuticals Inc's cost of sales deteriorated by -19.18 % year on year, relative to one quarter ago cost of sales fell by -44.48 % in Q1.

• More on CPRX Suppliers



Catalyst Pharmaceuticals Inc's cost of sales deteriorated by -19.18 % year on year, compare to one quarter ago cost of sales fell by -44.48 % in Q1.

• More on CPRX Suppliers




Catalyst Pharmaceuticals Inc's Comment on Supply Chain


The company is transitioning its final goods manufacturing to a U.S. location, with completion expected in 2026. It made a strategic investment in Santhera by acquiring 1,414,688 ordinary shares to support Phase IV studies of AGAMREE® and its development. Following FDA approval of Santhera's NDA for AGAMREE®, the company acquired the NDA and paid Santhera a $36 million milestone payment in the fourth quarter of 2023. Additional future milestone and royalty payments are contingent on sales performance. AGAMREE® is marketed in the U.S. through a dedicated field-based sales force and is supported by the Catalyst Pathways® patient services program. The company also donates to charitable foundations that provide financial assistance to patients with Duchenne muscular dystrophy (DMD) to ensure access to medication. Santhera is identified as a supplier in company filings.

Catalyst Pharmaceuticals Inc's Comment on Supply Chain


The company is transitioning its final goods manufacturing to a U.S. location, with completion expected in 2026. It made a strategic investment in Santhera by acquiring 1,414,688 ordinary shares to support Phase IV studies of AGAMREE® and its development. Following FDA approval of Santhera's NDA for AGAMREE®, the company acquired the NDA and paid Santhera a $36 million milestone payment in the fourth quarter of 2023. Additional future milestone and royalty payments are contingent on sales performance. AGAMREE® is marketed in the U.S. through a dedicated field-based sales force and is supported by the Catalyst Pathways® patient services program. The company also donates to charitable foundations that provide financial assistance to patients with Duchenne muscular dystrophy (DMD) to ensure access to medication. Santhera is identified as a supplier in company filings.







CPRX's vs. Suppliers, Data

(Revenue and Income for Trailing 12 Months, in Millions of $, except Employees)



COMPANY NAME MARKET CAP REVENUES INCOME EMPLOYEES
Catalyst Pharmaceuticals Inc 3,996.19 596.96 221.32 182
SUBTOTAL 0.00 0.00 0.00 -


Sources: Catalyst Pharmaceuticals Inc 's official press releases and regulatory filings; CSIMarket.com's supply-chain research; and the financial filings and press releases of other companies cited in this report.
Updated on:
For your research, we’ve provided nine additional tables on Catalyst Pharmaceuticals Inc ’s suppliers.
You can find them in the navigation menu under Suppliers.
To download the tables, please subscribe.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.